Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic
Human Secretin) when administered three times weekly to outpatients with obsessive compulsive
disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the
symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of
RG1068 on ODC patients' anxiety, quality of life, and depression.